Image: PetCure Oncology

Clinical Trials: Advancing Cancer Care for Pets

PetCure Oncology is on a mission to revolutionize pet cancer care with stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that has been proven effective in humans. To date, we’ve seen SRS/SRT treat many different types of pet cancers—and our specialists are determined to understand the safety and benefits of SRS/SRT on all tumors. That’s why PetCure Oncology is committed to clinical trials.

Whether you’re a pet parent or veterinarian, you may be able to take part in a clinical trial we’re currently conducting. Please see below for more information.

Fiducial trial

PetCure Oncology is currently recruiting participants for a clinical trial evaluating the effectiveness of stereotactic radiosurgery (SRS) combined with a liquid fiducial marker for the treatment of incompletely resected, grade 2 soft tissue sarcoma in dogs.


Historically, stereotactic radiation (SRS/SRT) has not been recommended for pets that have undergone surgery to remove a malignant tumor, primarily because there is no clearly definable treatment target. PetXMark, a liquid fiducial marker, can be injected along a surgical incision or painted into a resection cavity and will be visible on subsequent imaging. This allows an artificial target to be created that can then be treated with SRS in a single fraction, rather than the 19-21 fractions typically recommended for the treatment of an incompletely resected soft tissue sarcoma with conventionally fractionated radiation therapy (CFRT).



Lung tumor trial

As part of our ongoing commitment to clinical research, PetCure Oncology is launching a clinical trial to evaluate stereotactic radiosurgery (SRS) in the treatment of primary lung tumors in dogs.


Prior to the emergence of SRS, surgery was the primary treatment option for dogs diagnosed with lung tumors. But SRS has changed the way we approach cancer care for pets, offering noninvasive therapy with unprecedented precision that, in many cases, enables the treatment of tumors previously considered “untreatable.” If your pet has been diagnosed with a lung tumor, there may be hope. Studies have shown SRS to be successful in the treatment of lung tumors in humans. This study is intended to prove the hypothesis that dogs can also be safely and effectively treated for lung tumors with SRS.


If your dog has been diagnosed with a primary lung tumor, or if you are a veterinarian with a canine patient that has been diagnosed with one, they may be eligible for subsidized SRS treatment through this clinical trial.